COMMUNIQUÉS West-GlobeNewswire
-
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
02/04/2026 -
Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week
02/04/2026 -
Commure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor
02/04/2026 -
Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma
02/04/2026 -
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
02/04/2026 -
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
02/04/2026 -
Cartesian Therapeutics Announces New Employment Inducement Grants
02/04/2026 -
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
02/04/2026 -
Sienna Announces First Quarter 2026 Results Release Date and Conference Call
02/04/2026 -
Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
02/04/2026 -
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
02/04/2026 -
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
02/04/2026 -
PracticeLink Reveals Evolved Brand Identity Focused on Clarity, Simplicity and Trust for Healthcare Providers and Recruiters
02/04/2026 -
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026 -
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026 -
Arch Biopartners Closes Non-Brokered Private Placement
02/04/2026 -
MyGevity Announces Nationwide Launch of Integrated Health Data Platform
02/04/2026 -
Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein
02/04/2026 -
Burning Rock Announces Founder’s Purchase of Its ADSs
02/04/2026
Pages